An opening for AI in the medical field will likely go unrealised
The UK Government's research efforts into 'long Covid' may present an opportunity for artificial intelligence (AI) to prove its medical worth, but there will be challenges.
Comment
Wugen raises $172m to develop promising off-the-shelf NK cell therapies
Natural killer (NK) cell therapies in the T-cell acute lymphoblastic leukaemia (T-ALL) space have the...
Delta takes a hold in Southeast Asian countries – leading macroeconomic influencers
Southeast Asian countries struggle to contain a devastating third wave of Covid-19.
India may deploy Covid-19 vaccine boosters: Brazil, South Africa unlikely to follow soon
There’s increasing talk of vaccine boosters to combat the Delta variant. But what does this...
Higher education ruthlessly exploited amid Covid-19 – leading macroeconomic influencers
Covid-19 has amplified certain dynamics such as managerialism and economisation of universities.
mRNA vaccine booster shots and increasing uptake will offer CMOs opportunities
The discussed need for a Covid-19 vaccine booster in response to the existing variants will benefit pharma companies and CMOs.
Europe needs to get inflation above 2% target – leading macroeconomic influencers
Fear of inflation is stalking Europe.
Central banks’ new monetary policy remains open and flexible – leading macroeconomic influencers
The US Federal Reserve has committed to actively generate a period of inflation above 2%, while the ECB might passively tolerate a period of inflation above 2%.
Australia faces a double-dip recession – leading macroeconomic influencers
Lapses in Covid-19 vaccine procurement by the government has thrown Australia into turmoil with increasing transmission, increased restrictions and a likely second recession.
Covid-19 vaccine technologies and wider implications on vaccine success and uptake
The use of trusted technologies may help overcome the misinformation barriers that surround mRNA Covid-19 vaccine candidates.
Biogen expands its MS pipeline portfolio with a promising new agent
Biogen's recent partnership with InnoCare Pharma could establish the company as a strong player in the multiple sclerosis market.
